Brief: Ionis Receives US FDA Breakthrough Therapy Designation For ION582 In Angelman Syndrome
09/09/2025 12:03
Sept 9 (Reuters) - Ionis Pharmaceuticals Inc IONS.O: IONIS RECEIVES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION FOR ION582 IN ANGELMAN SYNDROME Source text: ID:nBw4KL3yka Further company coverage: IONS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors